Cytek Biosciences, Inc. (CTKB) Bundle
Understanding Cytek Biosciences, Inc. (CTKB) Revenue Streams
Understanding Cytek Biosciences, Inc. Revenue Streams
Total revenue for the three and nine months ended September 30, 2024 was $51.5 million and $143.0 million, respectively, representing a 7% increase and a 6% increase compared to total revenue of $48.0 million and $134.8 million for the same periods in 2023.
Revenue Breakdown by Source
The revenue streams are primarily categorized into product revenue and service revenue. For the three months ended September 30, 2024:
- Product revenue was $39.5 million, an increase of 3% from $38.4 million in 2023.
- Service revenue was $12.0 million, an increase of 25% from $9.6 million in 2023.
For the nine months ended September 30, 2024:
- Product revenue was $108.2 million, a decrease of 2% from $110.1 million in 2023.
- Service revenue was $34.7 million, an increase of 41% from $24.7 million in 2023.
Geographic Revenue Distribution
The geographical distribution of revenue for the three months ended September 30, 2024 was as follows:
| Region | Revenue (in thousands) | 2024 | 2023 |
|---|---|---|---|
| United States | $24,353 | $26,789 | |
| EMEA | $17,231 | $12,922 | |
| APAC | $8,937 | $6,757 | |
| Other | $979 | $1,532 |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rates are reflected in the following key metrics:
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Total Revenue Growth | 7% | 6% |
| Product Revenue Growth | 3% | -2% |
| Service Revenue Growth | 25% | 41% |
Contribution of Business Segments to Overall Revenue
The contribution of different business segments to overall revenue for the three months ended September 30, 2024 is as follows:
- Products contributed 76.7% of total revenue.
- Services contributed 23.3% of total revenue.
For the nine months ended September 30, 2024:
- Products contributed 75.3% of total revenue.
- Services contributed 24.7% of total revenue.
Significant Changes in Revenue Streams
The most significant change in revenue streams is the substantial growth in service revenue, which increased by $10.0 million for the nine months ended September 30, 2024, primarily due to a larger installed base of instruments generating service contracts and revenue.
A Deep Dive into Cytek Biosciences, Inc. (CTKB) Profitability
A Deep Dive into Cytek Biosciences, Inc.'s Profitability
Gross Profit Margin: For the three months ended September 30, 2024, the gross profit was $29.0 million with a gross margin of 56%, compared to $27.2 million and 57% for the same period in 2023. For the nine months ended September 30, 2024, gross profit was $77.5 million with a gross margin of 54%, down from $76.4 million and 57% in 2023.
Operating Profit: The loss from operations for the three months ended September 30, 2024 was $4.2 million, an improvement from a loss of $6.4 million in the same quarter of 2023. For the nine months ended September 30, 2024, the loss from operations was $23.5 million, down from $27.7 million in 2023.
Net Profit Margin: The net income for the three months ended September 30, 2024 was $941,000, compared to a net loss of $6.5 million in 2023. The net loss for the nine months ended September 30, 2024 was $15.7 million, an improvement from a loss of $17.7 million in the prior year.
Trends in Profitability Over Time
Over the past year, the company has shown a trend of improving operational efficiency and decreasing losses. The gross profit margin decreased slightly, but the company has managed to reduce operating losses significantly, indicating better cost management and revenue generation strategies.
Comparison of Profitability Ratios with Industry Averages
In comparison to industry averages, the gross margin of 56% for the third quarter of 2024 is slightly below the industry average of approximately 60%. However, the net income margin has improved from negative values to a marginal positive, which is a positive sign compared to the industry trend of net profitability.
Analysis of Operational Efficiency
Operational efficiency can be evaluated through several key metrics:
- Research and Development Expenses: Decreased to $9.9 million for Q3 2024 from $11.2 million in Q3 2023, reflecting a 12% reduction year-over-year.
- Sales and Marketing Expenses: Increased slightly to $12.4 million for Q3 2024 from $12.1 million in Q3 2023, but overall expenses for the nine-month period decreased by 1%.
- General and Administrative Expenses: Increased to $10.9 million for Q3 2024 from $10.4 million in Q3 2023, which indicates a 6% increase.
The total operating expenses for the nine months ended September 30, 2024, were $101.0 million, a decrease from $104.1 million in 2023.
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Gross Profit | $29.0 million | $27.2 million | +6.6% |
| Operating Loss | $4.2 million | $6.4 million | -34.4% |
| Net Income | $941,000 | $(6.5 million) | Improvement |
| Research and Development | $9.9 million | $11.2 million | -11.6% |
| Sales and Marketing | $12.4 million | $12.1 million | +2.5% |
| General and Administrative | $10.9 million | $10.4 million | +4.8% |
Debt vs. Equity: How Cytek Biosciences, Inc. (CTKB) Finances Its Growth
Debt vs. Equity: How Cytek Biosciences, Inc. Finances Its Growth
As of September 30, 2024, Cytek Biosciences, Inc. maintained a total debt of approximately $1.8 million from a fixed asset loan with a fixed interest rate of 4.5%. This loan was initially for $2.9 million and is set to mature in 2027. The current portion of this loan, which is $0.6 million, is included in other current liabilities.
In addition, on January 16, 2024, the company signed a credit agreement for 40 million Chinese renminbi (approximately $5.7 million), which is also collateralized by company assets. Furthermore, a new one-year loan agreement was established on February 28, 2024, amounting to 10 million Chinese renminbi (approximately $1.4 million) at an interest rate of 3.45%.
The debt-to-equity ratio is a critical metric for assessing the company’s financial leverage. As of September 30, 2024, Cytek's total stockholders' equity stood at approximately $389.1 million, resulting in a debt-to-equity ratio of approximately 0.005, indicating a conservative use of debt relative to equity.
To provide a clearer understanding of Cytek's financial structure, the following table summarizes its debt and equity components:
| Component | Amount (in millions) |
|---|---|
| Total Debt | $1.8 |
| Total Stockholders' Equity | $389.1 |
| Debt-to-Equity Ratio | 0.005 |
| Current Portion of Debt | $0.6 |
| Long-term Debt | $1.2 |
Cytek has focused on balancing its growth between debt financing and equity funding. The company primarily utilizes equity financing from its initial public offering (IPO) in July 2021, which raised approximately $215.7 million. Additionally, as of September 30, 2024, the company had about $277.8 million in cash and cash equivalents, indicating strong liquidity to support its operational and investment activities.
Recent financing activities reflect a strategic approach to managing cash flows, with $12.2 million used in financing activities for the nine months ended September 30, 2024, primarily driven by share repurchases. This approach allows Cytek to leverage its equity base while maintaining a low debt profile, optimizing its capital structure for future growth opportunities.
Assessing Cytek Biosciences, Inc. (CTKB) Liquidity
Assessing Cytek Biosciences, Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio of Cytek Biosciences, Inc. is approximately 5.02, calculated from current assets of $277.8 million and current liabilities of $55.3 million.
Quick Ratio: The quick ratio is approximately 4.78, considering the quick assets of $272.4 million (current assets minus inventory) against the same current liabilities of $55.3 million.
Analysis of Working Capital Trends
Working capital as of September 30, 2024, is $222.5 million, reflecting an increase from $207.4 million on December 31, 2023. This increase indicates a positive trend in liquidity management and operational efficiency.
| Period | Current Assets (in thousands) | Current Liabilities (in thousands) | Working Capital (in thousands) |
|---|---|---|---|
| September 30, 2024 | $277,800 | $55,300 | $222,500 |
| December 31, 2023 | $262,700 | $55,300 | $207,400 |
Cash Flow Statements Overview
Operating Cash Flow: For the nine months ended September 30, 2024, net cash provided by operating activities was $23.4 million, significantly improving from a cash outflow of $4.2 million in the prior year.
Investing Cash Flow: Net cash used in investing activities was $19.5 million for the same period, compared to $123 million in the previous year, indicating a reduction in capital expenditures and a more cautious investment approach.
Financing Cash Flow: Cash used in financing activities totaled $12.2 million, increasing from $8.1 million in the prior year, mainly due to share repurchases totaling $14.6 million.
| Cash Flow Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Operating Activities | $23,382 | $(4,231) |
| Investing Activities | $(19,541) | $(122,960) |
| Financing Activities | $(12,182) | $(8,058) |
Potential Liquidity Concerns or Strengths
The company maintains a strong liquidity position with cash and cash equivalents amounting to $162.3 million as of September 30, 2024. However, the increase in cash used for financing activities, particularly share repurchases, may raise concerns about future liquidity if operational cash flows do not improve further.
The anticipated cash flows from operations are expected to support working capital and capital expenditure needs for at least the next 12 months, indicating a robust liquidity outlook amid ongoing investments in research and development.
Is Cytek Biosciences, Inc. (CTKB) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis of the company focuses on key financial ratios, stock performance, and market sentiment to determine whether it is overvalued or undervalued.
Price-to-Earnings (P/E) Ratio
The P/E ratio is a critical indicator of valuation. As of September 30, 2024, the company reported a net income of $941,000 for the third quarter, resulting in a P/E ratio of approximately – (due to negative earnings in the previous periods). The diluted net income per share for the third quarter was $0.01.
Price-to-Book (P/B) Ratio
The company's book value as of September 30, 2024 was approximately $385.5 million with total shares outstanding of 131.5 million, leading to a P/B ratio of approximately 0.29 based on a stock price of around $3.85.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
As of September 30, 2024, the enterprise value is calculated as market capitalization plus total debt minus cash. With total liabilities of $105.8 million and cash and cash equivalents of $162.3 million, the enterprise value is approximately $– (as the company has more cash than liabilities). EBITDA for the last twelve months is approximately –, making the EV/EBITDA ratio –.
Stock Price Trends
Over the past 12 months, the stock has fluctuated significantly, reaching a high of approximately $8.00 and a low of $3.50. As of the latest close, the stock price is approximately $3.85, reflecting a decline of about – over the year.
Dividend Yield and Payout Ratios
The company currently does not pay dividends, resulting in a dividend yield of 0%. The payout ratio is also 0% due to the lack of dividend distributions.
Analyst Consensus
Analyst consensus on the stock valuation is mixed, with a majority rating it as a hold. Price targets among analysts range from $3.50 to $5.00.
| Metric | Value |
|---|---|
| P/E Ratio | – |
| P/B Ratio | 0.29 |
| EV/EBITDA Ratio | – |
| 12-Month High Stock Price | $8.00 |
| 12-Month Low Stock Price | $3.50 |
| Current Stock Price | $3.85 |
| Dividend Yield | 0% |
| Payout Ratio | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Cytek Biosciences, Inc. (CTKB)
Key Risks Facing Cytek Biosciences, Inc.
The financial health of Cytek Biosciences, Inc. is influenced by various internal and external risks that could impact its operations and profitability. Below are the key risk factors identified that investors should consider.
Industry Competition
The biotechnology and pharmaceutical sectors are characterized by intense competition. As of September 30, 2024, the company reported a total revenue of $51.5 million, reflecting a 7% increase compared to $48.0 million for the same period in 2023. Despite the growth, competition from established players and new entrants could affect market share and pricing strategies.
Regulatory Changes
Changes in regulations related to healthcare and biotechnology could pose risks. The company’s Northern Lights CLC system received CE Marking under the European Union In Vitro Diagnostic Medical Devices Directive in September 2020 and was registered as a Class II In Vitro Diagnostic Medical Device in China as of November 2023. Any regulatory changes could impact the company’s ability to sell its products in key markets.
Market Conditions
Macro-economic uncertainties, such as liquidity concerns and disruptions in the credit markets, have led to longer sales cycles. For instance, the company noted that macroeconomic factors contributed to a net loss of $15.7 million for the nine months ended September 30, 2024, compared to a net loss of $17.7 million for the same period in 2023.
Operational Risks
Operational risks include reliance on key personnel and the effectiveness of manufacturing processes. The company reported a gross profit of $29.0 million for the three months ended September 30, 2024, which may be affected by operational inefficiencies or disruptions in supply chains.
Financial Risks
As of September 30, 2024, the total liabilities stood at $105.8 million compared to total assets of $491.2 million. This indicates a substantial equity cushion, yet ongoing operational losses could lead to financial strain if not addressed. The company also reported interest expenses of $694,000 for the nine months ended September 30, 2024.
Strategic Risks
The company’s strategic initiatives, including new product development, come with inherent risks. Research and development expenses were $9.9 million for the three months ended September 30, 2024, a slight decrease from $11.2 million for the same period in 2023. Continued investment in R&D is crucial for maintaining competitive advantage but poses financial risk if products do not achieve market acceptance.
Mitigation Strategies
To mitigate these risks, the company has adopted a direct sales model in North America and Europe, which accounted for 77% of total revenue in the third quarter of 2024. Additionally, ongoing investments in R&D and commercial infrastructure are aimed at enhancing product offerings and market penetration.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Industry Competition | Intense competition in biotechnology and pharmaceuticals. | Revenue increased by 7% to $51.5 million in Q3 2024. |
| Regulatory Changes | Changes in healthcare regulations could impact product sales. | Potential sales restrictions in key markets. |
| Market Conditions | Macro-economic uncertainties affecting sales cycles. | Net loss of $15.7 million for 9 months ended Sep 2024. |
| Operational Risks | Reliance on key personnel and manufacturing processes. | Gross profit of $29.0 million in Q3 2024. |
| Financial Risks | Liabilities compared to assets and operational losses. | Interest expenses of $694,000 for 9 months ended Sep 2024. |
| Strategic Risks | Investment in R&D for new product development. | R&D expenses of $9.9 million in Q3 2024. |
Future Growth Prospects for Cytek Biosciences, Inc. (CTKB)
Future Growth Prospects for Cytek Biosciences, Inc.
Analysis of Key Growth Drivers
Key growth drivers for the company include:
- Product Innovations: The company continues to enhance its product portfolio, focusing on the Full Spectrum Profiling (FSP) technology that offers improved sensitivity and flexibility in cell analysis.
- Market Expansions: The company is expanding its reach in the EMEA and APAC regions, where instrument sales have shown significant growth.
- Acquisitions: The acquisition of the flow cytometry and imaging business from Luminex Corporation in February 2023 has broadened its product offerings and customer base.
Future Revenue Growth Projections and Earnings Estimates
For the three months ended September 30, 2024, total revenue reached $51.5 million, a 7% increase from $48.0 million in the same period of 2023. For the nine-month period ending September 30, 2024, revenue was $143.0 million, up 6% from $134.8 million in 2023.
Strategic Initiatives and Partnerships
Strategic initiatives driving future growth include:
- Increased R&D Investment: The company invested $9.9 million in R&D for Q3 2024, focusing on product development, compared to $11.2 million in Q3 2023.
- Sales and Marketing Expansion: Sales and marketing expenses were $12.4 million in Q3 2024, a slight increase from $12.1 million in Q3 2023, indicating a commitment to expanding market presence.
Competitive Advantages
The company holds several competitive advantages:
- Advanced Technology: The FSP technology provides superior multiplexing capabilities with lower operational costs compared to traditional methods.
- Strong Installed Base: The growth in service revenue by 25% in Q3 2024, compared to the same quarter in 2023, is a direct result of an expanding installed base of instruments.
- Global Reach: Direct sales accounted for 77% of total revenue in Q3 2024, indicating a robust direct sales strategy.
| Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | $51.5 million | $48.0 million | 7% |
| Product Revenue | $39.5 million | $38.4 million | 3% |
| Service Revenue | $12.0 million | $9.6 million | 25% |
| R&D Expenses | $9.9 million | $11.2 million | -12% |
| Sales and Marketing Expenses | $12.4 million | $12.1 million | 3% |
The company is strategically positioned to leverage these growth opportunities, supported by a solid financial foundation and ongoing commitment to innovation and market expansion.
Cytek Biosciences, Inc. (CTKB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Cytek Biosciences, Inc. (CTKB) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Cytek Biosciences, Inc. (CTKB)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Cytek Biosciences, Inc. (CTKB)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.